Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-229 phase I drug-drug interaction study with omeprazole, fexofenadine, and rosuvastatin in healthy adult male subjects
jRCT2071250131Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Mar 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NS-229, omeprazole, fexofenadine and rosuvastatin (2 arms), sponsored by Nippon Shinyaku. Primary endpoints: AUC of NS-229 and combination drugs and Cmax of NS-229 and combination drugs. Started Mar 2026; status: completed.
02
Drugs
NS-229omeprazolefexofenadinerosuvastatin
Beyond the preview
Go deeper on jRCT2071250131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250131.